Agomab to Participate in Upcoming Conferences
Rhea-AI Summary
Agomab Therapeutics (Nasdaq: AGMB) announced participation in several 2026 scientific and investor conferences. Events include a poster on AGMB-447 for idiopathic pulmonary fibrosis at the ATS International Conference and multiple fireside chats and investor meetings across New York, London, San Diego, and Boston.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AGMB
On the day this news was published, AGMB declined 1.25%, reflecting a mild negative market reaction. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $600.33M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No biotechnology peers from the provided list appeared in the momentum scanner, so the -7.45% move in AGMB looks stock-specific rather than part of a broader sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Earnings and outlook | Positive | +3.3% | Full-year 2025 results, cash runway into 1H 2029, and positive pipeline updates. |
| Mar 26 | Patent and pipeline | Positive | -7.7% | USPTO patent grant for AGMB-447 with protection through at least 2041. |
| Feb 09 | IPO completion | Neutral | -0.4% | Closing of IPO of 12,500,000 ADSs at $16.00, raising $200M gross proceeds. |
Recent news has shown mixed reactions: positive fundamental updates sometimes aligned with gains, while clearly positive IP and pipeline news once coincided with a notable selloff.
Over the last few months, Agomab moved from its February 2026 IPO to reporting full-year 2025 results and confirming its 2026 outlook, with cash of €116.5M and IPO proceeds expected to fund operations into the first half of 2029. It also secured a U.S. patent for AGMB-447 covering composition of matter through at least 2041. Against that backdrop, this announcement simply outlines a busy slate of scientific and investor conferences, extending ongoing investor and scientific outreach rather than changing fundamentals.
Market Pulse Summary
This announcement details a busy calendar of scientific and investor engagements, including an AGMB-447 poster at the ATS International Conference 2026 and multiple fireside chats and one-on-one meetings through July 15, 2026. In the past year Agomab has raised capital via IPO and reported cash expected to fund operations into the first half of 2029, alongside progress for ontunisertib and AGMB-447. Investors may watch upcoming trial initiations, data readouts, and partnering signals alongside feedback from these conferences.
Key Terms
TGFβR1/ALK5 inhibitor medical
idiopathic pulmonary fibrosis medical
preclinical species medical
AI-generated analysis. Not financial advice.
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:
- ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL.
- H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET in New York, NY.
- 2026 RBC Capital Markets Global Healthcare Conference. Fireside chat on Wednesday, May 20, 2026 at 8:00 AM ET in New York, NY.
- JPM European Healthcare Symposium. Wednesday, June 10, 2026 in London, UK.
- BIO International Convention. Monday, June 22 - Thursday, June 25, 2026 in San Diego, CA.
- 2026 Leerink Partners Therapeutics Forum. One-on-one investor meetings on Wednesday, July 15, 2026 in Boston, MA.
About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.
Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu
Phone: +49 172 861 8540
